Our Company
McNeil Pediatrics can trace its origins to the storefront pharmacy Robert McNeil opened in the Kensington section of Philadelphia in 1879. There, McNeil manufactured and sold high-quality medications that quickly won the professional endorsement of doctors and hospitals throughout the city. In the early 20th century, the business shifted away from retail operators and into the expanding pharmaceutical market. In 1933, the drug store was incorporated as McNeil Laboratories Inc., which specialized in the direct marketing of prescription pharmaceuticals to doctors and hospitals. In 1959, McNeil Laboratories was acquired by Johnson & Johnson. The company continued to thrive through the next four decades, building a leadership position in its markets.
Today, McNeil Pediatrics is a leader in Attention Deficit Hyperactivity Disorder (ADHD) treatment for children and adolescents with its drug CONCERTA®, (methylphenidate HCI), an extended release, once-a-day treatment featuring the exclusive OROS® delivery system. CONCERTA® is the number one medication prescribed in the U.S. for children and adolescents with ADHD.
IMPORTANT SAFETY INFORMATION
Talk to your doctor for a proper diagnosis and treatment of ADHD. Only a doctor can decide whether medication is right for you or your child.
CONCERTA® should not be taken by patients with: significant anxiety, tension, or agitation; allergies to methylphenidate or other ingredients in CONCERTA®; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome.
Abuse of methylphenidate may lead to dependence. Tell your healthcare professional if your child has had problems with alcohol or drugs, has had depression, abnormal thoughts or visions, bipolar disorder, seizures, high blood pressure or has had any heart problems or defects. If your child develops abnormal thinking or hallucinations, abnormal, extreme moods and/or excessive activity, or if aggressive behavior or hostility develops or worsens while taking CONCERTA®, consult your healthcare professional.
The most common adverse events reported in children receiving up to 54 mg were headache, upper respiratory tract infection and abdominal pain. The most common adverse events reported by adolescents receiving up to 72 mg were headache, accidental injury and insomnia.
See Full U.S. Prescribing Information and Medication Guide for CONCERTA®.
